Page last updated: 2024-11-05

cyproterone acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9880
CHEMBL ID139835
CHEBI ID50743
SCHEMBL ID5936
MeSH IDM0026384

Synonyms (145)

Synonym
smr000326769
MLS001066353
MLS002207305
BIDD:PXR0052
AB00698312-08
gtpl2865
cyprostat®
AKOS008901350
(1r,3as,3br,7ar,8as,8bs,8cs,10as)-1-acetyl-5-chloro-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate
EU-0100301
cyproterone acetate, >=98%
cyproterone 17alpha-acetate
1,2-alpha-methylene-6-chloro-(sup 4,6)-pregnadiene-17-alpha-ol-3,20-dione 17-alpha-acetate
6-chloro-1-beta,2-beta-dihydro-17-hydroxy-3'h-cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione 17-acetate
hsdb 3592
3'h-cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 6-chloro-1-beta,2-beta-dihydro-17-hydroxy-, acetate
1,2-alpha-methylene-6-chloro-delta(sup 6)-17-alpha-hydroxyprogesterone acetate
1,2-alpha-methylene-6-chloro-pregna-4,6-diene-3,20-dione 17-alpha-acetate
nsc 81430
einecs 207-048-3
6-chloro-17-hydroxy-1-alpha,2-alpha-methylenepregna-4,6-diene-3,20-dione acetate
pregna-4,6-diene-3,20-dione, 6-chloro-17-hydroxy-1-alpha,2-alpha-methylene-, acetate
ccris 4385
6-chloro-1,2-alpha-methylene-6-dehydro-17-alpha-hydroxyprogesterone acetate
6-chloro-delta(sup 6)-1,2-alpha-methylene-17-alpha-hydroxyprogesterone acetate
6-chloro-1beta,2beta-dihydro-17-hydroxy-3'h-cyclopropa(1,2)-pregna-1,4,6-triene-3,20-dione acetate
6-chloro-delta-6-1,2alpha-methylene-17alpha-hydroxyprogesterone acetate
6-chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteronacetat [german]
6-chloro-1,2-alpha-methylene-17-alpha-hydroxy-delta(sup 6)-progesterone acetate
17-alpha-acetoxy-6-chloro-1-alpha,2-alpha-methylenepregna-4,6-diene-3,20-dione
progesterone,2.alpha.-methylene, acetate
1,6)-pregnadiene-17.alpha.-ol-3,20-dione acetate
427-51-0
nsc-81430
3'h-cyclopropa[1,4,6-triene-3,20-dione, 6-chloro-1.beta.,2.beta.-dihydro-17-hydroxy-, acetate
cyproterone 17.alpha.-acetate
sh-714
3'h-cyclopropa[1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1.beta.,2.beta.)-
sh 714
progesterone,2.alpha.-methylene-, acetate
6-chloro-17-hydroxy-1.alpha.,6-diene-3,20-dione acetate
androcur
6-chloro-1,2.alpha.-methylene-17.alpha.-hydroxy-.delta.(sup 6)-progesterone acetate
cyprosterone acetate
17.alpha.-acetoxy-6-chloro-1.alpha.,6-diene-3,20-dione
3'h-cyclopropa[1,4,6-triene-3,20-dione, 6-chloro-1.beta.,2.beta.-dihydro-17-hydroxy-,acetate
1,6)-pregnadiene-17.alpha.-ol-3,20-dione 17alpha-acetate
pregna-4,20-dione, 6-chloro-17-hydroxy-1.alpha.,2.alpha.-methylene-, acetate
1,6)-pregnadeine-17.alpha.-3,20-dione acetate
1,2.alpha.-methylene-6-chloro-.delta.(sup 6)-17.alpha.-hydroxyprogesterone acetate
6-chloro-1.beta.,2]pregna-1,4,6-triene-3,20-dione acetate
cyproteron acetate
6-chloro-1,2.alpha.-methylene-6-dehydro-17.alpha.-hydroxyprogesterone acetate
6-chloro-.delta.(sup 6)-1,2.alpha.-methylene-17.alpha.-hydroxyprogesterone acetate
1,6-diene-3,20-dione 17.alpha.-acetate
wln: l f3 e6 d665 iv ju lutj a1 e1 rv1 rq
cyproteron-r acetate
nsc81430
CYPROTERONE ACETATE ,
sh 80714
cyproterone 17-o-acetate
cyproteroneacetate
(acetyl-chloro-dimethyl-oxo-[?]yl) acetate
3'h-cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-
LOPAC0_000301
acetic acid (8r,9s,10s,13s,14s,17r)-17-acetyl-6-(s)-chloro-10,13-dimethyl-3-(r)-oxo-1,2,3,8,9,10,11,12,13,14,15,16,17,20-tetradecahydro-cyclopropa[1,2]cyclopenta[a]phenanthren-17-yl ester
CHEBI:50743 ,
6-chloro-3,20-dioxo-1beta,2beta-dihydro-3'h-cyclopropa[1,2]pregna-4,6-dien-17-yl acetate
NCGC00091032-01
DB04839
MLS000859908 ,
D01368
NCGC00091032-03
smr000686068
MLS001055462
HMS2090A14
AC-929
C 3412
NCGC00091032-04
6-chloro-3,20-dioxo-1beta,2beta-dihydro-3''h-cyclopropa[1,2]pregna-4,6-dien-17-yl acetate
bdbm50094569
cid_9880
CHEMBL139835 ,
NCGC00091032-05
HMS3260N04
unii-4km2bn5jhf
cyprostat
6-chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteronacetat
4km2bn5jhf ,
dtxcid30366
NCGC00256442-01
tox21_302941
dtxsid5020366 ,
(1s,2s,3s,12s,16s,5r,11r,15r)-15-acetyl-9-chloro-2,16-dimethyl-6-oxopentacyclo [9.7.0.0<2,8>.0<3,5>.0<12,16>]octadeca-7,9-dien-15-yl acetate
tox21_201686
NCGC00259235-01
tox21_111064
CCG-204396
HMS2233J06
LP00301
cyproterone acetate [ep monograph]
6-chloro-3,20-dioxo-1beta,2beta-dihydro-3'h-cyclopropa[1,2]pregna-1,4,6-trien-17-yl acetate
cyproterone acetate [jan]
cyproterone acetate [mart.]
cyproterone acetate [hsdb]
cyproterone acetate [usan]
sh714
(1beta,2beta)-17-(acetyloxy)-6-chloro-1,2-dihydro-3'h-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione
cyproterone acetate [who-dd]
cyproterone acetate [mi]
3'h-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-
6-chloro-17-hydroxy-1alpha,2alpha-methylenepregna-4,6-diene-3,20-dione acetate
3'h-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1.beta.,2.beta.)-
2OZ7
S2042
AKOS015895238
DL-368
6-chloro-17-acetoxy-1alpha,2alpha-methylene-4,6-pregnadiene-3,20-dione
17alpha-acetoxy-6-chloro-1alpha,2alpha-methylene-4,6-pregnadiene-3,20-dione
MLS006011110
SCHEMBL5936
NCGC00262575-02
tox21_111064_1
tox21_500301
NCGC00260986-01
W-106262
C2942
cyproterone acetate, european pharmacopoeia (ep) reference standard
sr-01000075755
SR-01000075755-6
(2ar,3as,3bs,3cs,5as,6r,8as,8br)-6-acetyl-10-chloro-3b,5a-dimethyl-2-oxo-2,2a,3,3a,3b,3c,4,5,5a,6,7,8,8a,8b-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-6-yl acetate
cyproterone acetate for peak identification, european pharmacopoeia (ep) reference standard
SR-01000075755-4
SR-01000075755-1
NCGC00091032-09
Q426185
mfcd00864671
BRD-K41141507-001-16-2
SDCCGSBI-0050289.P002
NCGC00091032-12
cyproterone-acetate
cyproterone acetate for peak identification
cyproterone acetate assay standard
EN300-19765943
(1s,2s,3s,5r,11r,12s,15r,16s)-15-acetyl-9-chloro-2,16-dimethyl-6-oxopentacyclo[9.7.0.0^{2,8}.0^{3,5}.0^{12,16}]octadeca-7,9-dien-15-yl acetate

Research Excerpts

Overview

Cyproterone acetate (CPA) is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. It is a steroidal anti-androgen that has been used in human medicine for contraceptive purposes.

ExcerptReferenceRelevance
"Cyproterone acetate (CPA) is a competitive inhibitor of the androgen receptor and exerts negative hypothalamic feedback. "( Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study.
Conemans, EB; den Heijer, M; Fisher, AD; Kuijpers, SME; T'Sjoen, G; Wiepjes, CM, 2021
)
2.34
"Cyproterone acetate (CA) is an antiandrogenic progestin commonly used in adult transwomen to suppress endogenous androgens, often in combination with estrogens to induce feminization."( Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents.
Bossche, HV; Cools, M; Craen, M; Dhondt, K; Heyse, R; Laridaen, J; Tack, LJW, 2017
)
2.28
"Cyproterone acetate (CPA) is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. "( Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report.
Champagne, PO; Froelich, S; Passeri, T, 2019
)
2.24
"Cyproterone acetate is a steroidal anti-androgen that has been used in human medicine for contraceptive purposes as well as treatment of medical conditions responsive to suppression of testosterone production. "( Fatal fulminant hepatitis in a chimpanzee (Pan troglodytes) receiving cyproterone acetate.
Geschke, K; Pease, C; Roe, WD, 2009
)
2.03
"Cyproterone acetate (CPA) is an oral anti-androgen commonly used to treat advanced prostate cancer. "( Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report.
Abenavoli, L; Beaugrand, M; Milic, N,
)
1.87
"Cyproterone acetate (CPA) is a synthetic antiandrogenic compound which is widely used in clinic but suspected to be hepatocarcinogenic. "( Long term phenobarbital administration does not promote the multiplication of hepatocytes replicating after single cyproterone acetate administration.
Ferry, N; Pichard, V, 2005
)
1.98
"Cyproterone acetate (CPA) is a steroideal antiandrogen which has affinity with progesteron and with glucocorticoidal receptors."( Cyproterone acetate in the therapy of prostate carcinoma.
Floriani, I; Torri, V, 2005
)
2.49
"Cyproterone acetate (CPA) is a steroidal synthetic progestagen and anti-androgenic compound widely administered in prostate cancer which has been evidentially correlated with a severe hepatotoxic potency. "( Hepatotoxicity induced by cyproterone acetate: a report of three cases.
Deutsch, M; Dourakis, SP; Kafiri, G; Koudouras, D; Savidou, I; Soultati, AS, 2006
)
2.08
"Cyproterone acetate (CPA) is a steroidal antiandrogen used clinically in the treatment of prostate cancer. "( Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.
Bell, CE; Bohl, CE; Dalton, JT; Miller, DD; Wu, Z, 2007
)
2
"Cyproterone acetate acts as an antiandrogen through competitive inhibition of the androgens at cellular level on the peripheral effectors. "( [Anti-androgens. Their use in dermatology].
Arevalo, A; Michelotti, M; Montero, ED, 1981
)
1.71
"Cyproterone acetate (CPA) is a synthetic steroid which is widely used in antiandrogenic and gestagenic drugs. "( Accumulation and persistence of DNA adducts of the synthetic steroid cyproterone acetate in rat liver.
Schwarz, LR; Topinka, J; Werner, S; Wolff, T, 1995
)
1.97
"Cyproterone acetate (CPA) is a synthetic steroid hormone used in the therapy of prostate cancer in men and different forms of acne and hirsutism in women. "( Identification of 3 alpha-hydroxy-cyproterone acetate as a metabolite of cyproterone acetate in the bile of female rats and the potential of this and other already known or putative metabolites to form DNA adducts in vitro.
Baumann, A; Biere, H; Blode, H; Brudny-Klöppel, M; Kerdar, RS; Kuhnz, W, 1995
)
2.01
"Cyproterone acetate (CPA) is a synthetic steroid which is used in oral contraceptive and anti-androgen formulations. "( Initiation of enzyme-altered foci by the synthetic steroid cyproterone acetate in rat liver foci bioassay.
Deml, E; Oesterle, D; Schwarz, LR, 1993
)
1.97
"Cyproterone acetate is a powerful antiandrogen used in the treatment of the paraphilias for at least a decade. "( Double-blind placebo crossover study of cyproterone acetate in the treatment of the paraphilias.
Bradford, JM; Pawlak, A, 1993
)
2
"Cyproterone acetate (CPA) is an antiandrogenic compound that shows a rhythmic toxicologic behaviour. "( Chronopharmacokinetic behaviour of cyproterone acetate in rabbits.
Boggio, JC; Encinas, T; Rodríguez, C; San Andrés, MD; San Andrés, MI; Vinagre, E,
)
1.85
"Cyproterone acetate is a normally well-tolerated drug that is used widely for the treatment of prostatic carcinoma. "( Fatal fulminant hepatic failure due to cyproterone acetate.
Friedman, G; Lamoureux, E; Sherker, AH, 1999
)
2.02
"Cyproterone acetate is a potent antiandrogen with strong progestational activity. "( [The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type].
Albring, M; Brill, K; Gollnick, H, 1999
)
2.04
"Cyproterone acetate is a steroidal anti-androgen that blocks the androgen-receptor interaction and reduces serum testosterone through its weak anti-gonadotropic action. "( The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.
de Voogt, HJ, 1992
)
2.07
"Cyproterone acetate is a progestational antiandrogen with potent antigonadotropic activity that results in rapid suppression of serum testosterone. "( Use of cyproterone acetate in prostate cancer.
Bruchovsky, N; Goldenberg, SL, 1991
)
2.18
"Cyproterone acetate (CPA) is a widely used drug in the treatment of advanced prostatic carcinoma. "( Severe hepatocellular dysfunction following cyproterone acetate therapy.
Hamid, S; Parys, BT; Thomson, RG, 1991
)
1.99
"Cyproterone acetate (CPA) is a synthetic progestogen which possesses antiandrogenic properties with some synandrogenic action."( [Effects of cyproterone acetate on mouse submandibular gland].
Ichikawa, M; Maruyama, S, 1989
)
1.38
"Cyproterone acetate is a steroidal antiandrogen with weak progestational activity that results in the partial suppression of pituitary gonadotropin. "( The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
Bruchovsky, N; Coppin, CM; Goldenberg, SL; Rennie, PS, 1988
)
2.05

Effects

Cyproterone acetate has a stronger inhibitory effect than megestrol acetate (MGA) and flutamide (FL) on the prostate and seminal vesicle of intact adult rats. Cy Proterone Acetate has additional known risks, such as meningioma. Although we cannot conclusively prove that it has a role in the development of hypertension, we conclude that the use of cyproter one acetate should be reconsidered.

ExcerptReferenceRelevance
"Cyproterone acetate (CPA) has a stronger inhibitory effect than megestrol acetate (MGA) and flutamide (FL) on the prostate and seminal vesicle of intact adult rats. "( Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats.
el Etreby, MF; Habenicht, UF; Louton, T; Nishino, Y; Schröder, HG, 1987
)
2.12
"Cyproterone acetate has additional known risks, such as meningioma; although we cannot conclusively prove that it has a role in the development of hypertension, we conclude that the use of cyproterone acetate for this indication should be reconsidered."( Incidence of hypertension in young transgender people after a 5-year follow-up: association with gender-affirming hormonal therapy.
Acosta-Calero, C; Arnas-Leon, C; de Leon-Durango, RJ; Del Pino Perez-Garcia, M; Del Sol Sanchez-Bacaicoa, M; Fernandez-Trujillo-Comenge, PM; Gonzalez-Diaz, P; Hernandez-Lazaro, A; Kuzior, A; Martinez-Martin, FJ; Perdomo-Herrera, E; Perez-Rivero, JM; Rios-Gomez, C; Santana-Ojeda, B; Tocino-Hernandez, AL, 2023
)
1.63
"Cyproterone acetate (CPA) has been discovered more than 25 years ago and it was the first antiandrogen suitable for clinical use. "( Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience.
Kalmus, J; Neumann, F, 1991
)
3.17
"Cyproterone acetate, however, has properties conventionally ascribed to both synthetic androgens (e.g."( Paradoxical effects of the anti-androgen cyproterone acetate on lipid and lipoprotein metabolism.
Godsland, IF; Jacobs, HS; Seed, M; Wynn, V, 1986
)
1.26
"Cyproterone acetate (CPA) has a stronger inhibitory effect than megestrol acetate (MGA) and flutamide (FL) on the prostate and seminal vesicle of intact adult rats. "( Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats.
el Etreby, MF; Habenicht, UF; Louton, T; Nishino, Y; Schröder, HG, 1987
)
2.12

Actions

ExcerptReferenceRelevance
"Cyproterone acetate did not inhibit spermatogenesis but all males were infertile."( Sexual maturation in male mice treated with cyproterone acetate from birth to puberty.
Berger, M; De Turckheim, M; Jean, C; Jean-Faucher, C; Veyssiere, G, 1984
)
1.25

Treatment

Cyproterone acetate treatment was applied with good success by the authors to 52 patients with hirsutism. Cy Proterone Acetate did not change the salt-water balance or the plasma volume in such a way that the risk of congestive heart failure could be increased.

ExcerptReferenceRelevance
"Cyproterone acetate treatment also increased DR5 gene promoter activity, which could be abolished by mutation of a consensus binding domain of transcription factor CCAAT-enhancer-binding protein homologous protein (CHOP) in the DR5 gene promoter."( Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5.
Chen, L; Lin, MF; Tu, Y; Wolff, DW; Xie, Y, 2017
)
2.62
"Cyproterone acetate treatment induced a highly significant raise in plasma prolactin, a fact which may explain the less favourable clinical results in this group."( Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. A randomized clinical and endocrine study.
Aakvaag, A; Nissen-Meyer, R; Sander, S, 1982
)
1.29
"Cyproterone acetate treatment was applied with good success by the authors to 52 patients with hirsutism. "( [Personality and the social significance of hirsutism].
Csömör, S; Gimes, R; Lux, E; Rusz, E, 1982
)
1.71
"Cyproterone acetate treatment did not affect the concentration of any element in rete testis fluid or serum."( The effects of cyproterone acetate on the elements in the intraluminal fluids of the testis and epididymis of the rat.
Howards, SS; Jenkins, AD; Lechene, CP, 1983
)
1.34
"Cyproterone acetate treatment does not change the salt-water balance or the plasma volume in such a way that the risk of congestive heart failure could be increased."( Effects of oestrogens, orchidectomy and cyproterone acetate on salt and water metabolism in carcinoma of the prostate.
Karlberg, BE; Varenhorst, E; Wallentin, L; Wranne, B, 1981
)
1.25
"Cyproterone acetate treatment in the diabetic pseudopregnant rat resulted in a simultaneous elevation of oestradiol and progesterone, which eventually helped the endometrial differentiation to decidua in the diabetic pseudopregnant rat parallel to controls."( Cyproterone acetate and reversal of the impaired endometrial decidualization in streptozotocin-diabetic pseudopregnant rats.
Chatterjee, A; Ismail, Z; Zakaria, R, 2000
)
2.47
"Cyproterone acetate treatment (CA; 1 mg/fish daily for 21 days) from the second day of castration decreased the size and weight of the SV and the concentrations of total proteins, hexosamines, fructose and sialic acid."( Castration-induced hyperactivity of seminal vesicle in the catfish Clarias batrachus: a case of paradox and blockade by antiandrogen (cyproterone acetate) treatment.
Joy, KP; Singh, MS, 2001
)
1.24
"Cyproterone acetate treatment was more effective when other signs were present and when the BMI was elevated, factors that favoured a diagnosis of biochemical hyperandrogenism."( Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial.
Boudou, P; Chaspoux, C; Fiet, J; Hardy, N; Jouanique, C; Reygagne, P; Vexiau, P, 2002
)
1.33
"The cyproterone acetate-chronically treated rats showed higher beta-EP concentrations than vehicle-treated rats and these changes were reversed by the concomitant addition of dihydrotestosterone or dehydroepiandrosterone sulphate."( Effect of steroid hormones and antihormones on hypothalamic beta-endorphin concentrations in intact and castrated female rats.
Bergamaschi, M; Brilli, G; DeRamundo, BM; Genazzani, AD; Genazzani, AR; Mercuri, N; Petraglia, F; Volpe, A, 1990
)
0.76
"Cyproterone acetate in treatment of women exhibiting androgenization symptoms acts primarily by competitive suppression of the androgens in the target organs."( [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)].
Huber, J; Schmidt, JB; Spona, J, 1986
)
1.12
"Cyproterone acetate treatment from 1 to 10 days resulted in a definitive reduction in the relative weights of all accessory sex organs studied and when injected from 11 to 20 days in epididymis and vas deferens."( Permanent changes in the functional development of accessory sex organs and in fertility in male mice after neonatal exposure to cyproterone acetate.
Berger, M; De Turckheim, M; Jean, C; Jean-Faucher, C; Veyssiere, G, 1985
)
1.2
"Treatment of cyproterone acetate, an antiandrogen reagent, increased production of VTG with DHT."( Vitellogenin synthesis via androgens in primary cultures of tilapia hepatocytes.
Kim, BH; Kim, SJ; Lee, YD; Takemura, A, 2003
)
0.67
"Treatment of cyproterone acetate (10 mg kg(-1)) was scheduled from day 5 through day 9 p.c."( Cyproterone acetate and reversal of the impaired endometrial decidualization in streptozotocin-diabetic pseudopregnant rats.
Chatterjee, A; Ismail, Z; Zakaria, R, 2000
)
2.1
"Treatment with cyproterone acetate significantly decreased TG/FFA cycling in perigenital (epididymal) tissue."( Sex difference in triglyceride/fatty acid substrate cycling of rat adipose tissue: indirect regulation by androgens.
Hansson, P; Nilsson-Ehle, P; Saggerson, D, 1991
)
0.62
"Treatment with cyproterone acetate (50-100 mg/day) in 26 girls resulted in arrest of breast development and suppression of menstruation, but a definite effect on growth was not documented."( Isosexual precocious puberty in girls.
De Bruyn, R; Grant, DB; Lyon, AJ, 1985
)
0.61

Toxicity

ExcerptReferenceRelevance
" Climacteric symptoms, Kupperman index scores and potential adverse progestogen effects were recorded before treatment and three times per month during therapy."( Progestogens: therapeutic and adverse effects in early post-menopausal women.
Christiansen, C; Marslew, U; Riis, B, 1991
)
0.28
" and, especially, the presence of previous cardiovascular disease represented adverse factors in the development of cardiovascular toxicity."( Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer tria
de Pauw, M; de Voogt, HJ; Pavone-Macaluso, M; Smith, PH; Suciu, S, 1986
)
0.52
"These data suggest that both therapies were similarly effective and safe in the treatment of hirsutism."( Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism.
Başogul, O; Inal, M; Ispahi, C; Karanfil, C; Onoglu, A; Taner, C; Tinar, S, 2002
)
0.31
" This analysis could increase the information related to these adverse reactions mainly available from the published isolated cases."( Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system.
Hidalgo, A; Manso, G; Revuelta, P; Salgueiro, E; Thole, Z, 2006
)
0.33
"Liver disorders were the most common adverse reactions associated with flutamide and bicalutamide, but not with cyproterone acetate."( Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system.
Hidalgo, A; Manso, G; Revuelta, P; Salgueiro, E; Thole, Z, 2006
)
0.54
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The information about its toxic mechanism and risk factors is limited, based on pharmacovigilance reports and published case reports only."( [Hepatotoxicity induced by cyproteron acetate in the prostate carcinoma treatment - a case report].
Cerný, D; Röderová, E; Sálek, T; Vodička, M, 2013
)
0.39
"The aim of this study is to report the short-term effects of CHT on hormonal and clinical changes, side effects, and adverse events in trans men (female-to-male gender dysphoric persons) and trans women (male-to-female gender dysphoric persons)."( Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
Fisher, A; Fisher, AD; Haraldsen, I; Kaufman, JM; Schreiner, T; T'Sjoen, G; Toye, K; Van Caenegem, E; Wierckx, K, 2014
)
0.4
" Side effects, adverse events, and desired clinical changes were examined."( Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
Fisher, A; Fisher, AD; Haraldsen, I; Kaufman, JM; Schreiner, T; T'Sjoen, G; Toye, K; Van Caenegem, E; Wierckx, K, 2014
)
0.4
"No deaths or severe adverse events were observed."( Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
Fisher, A; Fisher, AD; Haraldsen, I; Kaufman, JM; Schreiner, T; T'Sjoen, G; Toye, K; Van Caenegem, E; Wierckx, K, 2014
)
0.4
"Current treatment modalities were effective and carried a low risk for side effects and adverse events at short-time follow-up."( Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
Fisher, A; Fisher, AD; Haraldsen, I; Kaufman, JM; Schreiner, T; T'Sjoen, G; Toye, K; Van Caenegem, E; Wierckx, K, 2014
)
0.4
" No major adverse effects were registered in either group."( Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness.
Battista, G; Cerpolini, S; Gava, G; Martelli, V; Meriggiola, MC; Seracchioli, R, 2016
)
1.88
"Limited data are available on adverse drug reactions (ADRs) of gender-affirming hormone therapy (HT), mainly due to the lack of population-based studies with adequate controls, thus making spontaneous reporting systems a valuable tool to detect potential side reactions."( Adverse effects of gender-affirming hormonal therapy in transgender persons: Assessing reports in the French pharmacovigilance database.
El Aridi, L; Feigerlova, E; Gillet, P; Klein, M; Maurier, A; Yelehe, M, 2022
)
0.72

Pharmacokinetics

The pharmacokinetic parameters, area under the serum concentration-time curve, apparent volume of distribution, apparent clearance, terminal half-life and the concentration ratio of 15 beta-hydroxycyproterone acetate were examined for possible age-dependence.

ExcerptReferenceRelevance
" At the end of treatment cycle three, the terminal half-life of CPA had increased to a mean value of 78."( Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
Jütting, G; Kuhnz, W; Staks, T, 1993
)
0.61
" The terminal half-life of CPA was higher at the end of treatment cycle 3 than after a single dose (78."( Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
Jütting, G; Kuhnz, W; Staks, T, 1993
)
0.61
" The pharmacokinetic parameters, area under the serum concentration-time curve, apparent volume of distribution, apparent clearance, terminal half-life and the concentration ratio of 15 beta-hydroxycyproterone acetate/cyproterone acetate were examined for possible age-dependence using regression analysis."( Investigation into the age-dependence of the pharmacokinetics of cyproterone acetate in healthy male volunteers.
Fuhrmeister, A; Kuhnz, W; Kulmann, H, 1997
)
0.72
" There was also a clear dependence of the terminal half-life on age."( Investigation into the age-dependence of the pharmacokinetics of cyproterone acetate in healthy male volunteers.
Fuhrmeister, A; Kuhnz, W; Kulmann, H, 1997
)
0.53
" Combined, the two effects cause a clear age-dependence of the terminal half-life of cyproterone acetate."( Investigation into the age-dependence of the pharmacokinetics of cyproterone acetate in healthy male volunteers.
Fuhrmeister, A; Kuhnz, W; Kulmann, H, 1997
)
0.76
"40%) for Cmax and 96."( Cyproterone acetate quantification in human plasma by high-performance liquid chromatography coupled to atmospheric pressure photoionization tandem mass spectrometry. Application to a comparative pharmacokinetics study.
Astigarraga, RB; Borges, NC; da Silva, WM; Galvinas, PA; Mazuqueli, A; Moreno, RA; Sampaio, MR; Sverdloff, CE, 2009
)
1.8

Compound-Compound Interactions

This prospective randomized phase III trial compares orchidectomy as standard androgen-deprivative therapy of advanced (metastatic) prostatic cancer with treatment using the LHRH agonist Buserelin administered as nasal spray.

ExcerptReferenceRelevance
" This 12-mo study was carried out to investigate the effects of orchiectomy, alone and in combination with testosterone, and of treatment with cyproterone acetate on pancreatic carcinogenesis in azaserine-treated rats and BOP-treated hamsters."( Effects of orchiectomy, alone or in combination with testosterone, and cyproterone acetate on exocrine pancreatic carcinogenesis in rats and hamsters.
de Jong, FH; Foekens, JA; Klijn, JG; Lamberts, SW; Meijers, M; van Garderen-Hoetmer, A; Visser, CJ; Woutersen, RA, 1992
)
0.72
" The four groups receiving hormone replacement therapy were given 2 mg estradiol valerate equivalents (E), either sequentially combined with 75 micrograms levonorgestrel (E/LNG), 10 mg medroxyprogesterone acetate (E/MPA), or 150 micrograms desogestrel (E/DG), or continuously combined with 1 mg cyproterone acetate (E/CPA)."( Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
Christiansen, C; Haarbo, J; Hassager, C; Jensen, SB; Riis, BJ, 1991
)
0.46
"The metabolic effects of cyproterone acetate (2 mg) combined with a new dose level of ethinyl estradiol (35 micrograms) were studied over a one-year period in 31 patients presenting moderate clinical hyperandrogenism."( Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 micrograms) in 31 patients.
Cathelineau, G; Fiet, J; Hardy, N; Martineau, I; Vexiau, P; Vexiau-Robert, D; Villette, JM, 1990
)
0.84
"This prospective randomized phase III trial compares orchidectomy as standard androgen-deprivative therapy of advanced (metastatic) prostatic cancer with treatment using the LHRH agonist Buserelin administered as nasal spray 3 daily doses of 400 micrograms, and combined with cyproterone acetate (CPA) 3 daily doses of 50 mg orally for 2 weeks initially to prevent flare-up of the disease, or continuously as complete androgen blockade."( Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
De Pauw, M; de Voogt, HJ; Klijn, JG; Schröder, F; Studer, U; Sylvester, R, 1990
)
0.71
" In order to investigate the optimal way to eliminate tumor flare, we have treated patients with one of three different antiandrogen regimens used in combination with gonadotrophin-releasing hormone (GnRH) agonist."( The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
Abel, P; Cox, J; Farah, N; Fleming, J; Hewitt, G; O'Donoghue, EP; Sandow, J; Sikora, K; Waxman, J; Williams, G, 1988
)
0.27
" Thirty-one male-to-female transsexuals, treated at least 3 months either with 100 mg CA alone or in combination with 50 micrograms ethinyloestradiol (EO)/day, were studied."( The effect of cyproterone acetate alone and in combination with ethinylestradiol on the hypothalamic pituitary adrenal axis, prolactin and growth hormone release in male-to-female transsexuals.
de Vries, CP; Gooren, LJ; van der Veen, EA, 1986
)
0.63
" A multicenter study was therefore done, in which two preparations containing CA in combination with ethinylestradiol (EE) were compared with a marketed combined oral contraceptive pill."( Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study.
Carlborg, L, 1986
)
1.71
"The effects of serum lipids and lipoproteins of 2 mg cyproterone acetate (CPA) given alone and in combination with 35 or 50 micrograms ethinyl estradiol (EE) were studied in 21 oophorectomized women in a study with a cross-over design."( Effects of cyproterone acetate (CPA) on serum lipoproteins when administered alone and in combination with ethinyl estradiol (EE).
Crona, N; Enk, L; Lindberg, UB; Samsioe, G; Silfverstolpe, G, 1987
)
0.91
" In the first phase of the treatment it was administered in combination with cyproterone acetate (CyA) to counteract an early stimulatory effect until inhibition of gonadotrophin secretion was achieved."( Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate-further experience.
Ben-Zeev, Z; Kaufman, H; Kauli, R; Laron, Z; Lewin, RP; Pertzelan, A; Schally, AM; Schally, AV, 1984
)
0.73
" However, the effect of long term treatment with GnRH in combination with an antiandrogen (cyproterone acetate) to block the possible effect of adrenal androgens has not previously been evaluated."( Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrog
Juul, A; Krabbe, S; Müller, J; Nielsen, CT; Scheike, T; Skakkebaek, NE, 1995
)
0.51
"To compare triptorelin, cyproterone acetate (CPA), and flutamide, in combination with an oral contraceptive, in the treatment of hirsutism."( Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism.
Balsa, J; Escobar-Morreale, HF; Pazos, F; Sancho, JM; Varela, C, 1999
)
0.82
" In combination with ethinyloestradiol, it has been shown to be of clinical benefit to women displaying signs of androgenization, such as acne, seborrhoea and hirsutism."( [The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type].
Albring, M; Brill, K; Gollnick, H, 1999
)
0.6
"Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS)."( The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.
de Vries, CS; Farmer, RD; Seaman, HE, 2003
)
2.01
"To explore the risk of liver disorders associated with cyproterone acetate combined with ethinyloestradiol (CPA/EE)."( The risk of liver disorders in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested case-control study using the GPRD.
de Vries, CS; Farmer, RD; Seaman, HE,
)
0.63
"To study the endocrinologic and metabolic effects of metformin in combination with compound cyproterone acetate (CPA) on patients with polycystic ovarian syndrome (PCOS)."( [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
Lin, JJ; Lin, WQ; Yang, HY; Ye, BL; Zhao, JZ, 2003
)
0.77
"The PCOS patients treated with metformin in combination with compound cyproterone acetate may be more effective in inhibiting hyperandrogen and hypersecretion of LH than metformin alone and more obvious in improving lipid profiles than CPA alone."( [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
Lin, JJ; Lin, WQ; Yang, HY; Ye, BL; Zhao, JZ, 2003
)
0.78
"To derive risk estimates for venous thromboembolism (VTE) in women prescribed cyproterone acetate combined with ethinyloestradiol (CPA/EE), a drug licensed in the UK for the treatment of women with acne or hirsutism."( Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database.
de Vries, CS; Farmer, RD; Seaman, HE, 2004
)
0.82
"In order to explore the effects of metformin combined with cyproterone acetate (CPA) on the clinical features, endocrine and metabolism of the patients with polycystic ovarian syndrome (PCOS), 50 cases of non-obese PCOS were randomly subjected to CPA (CPA treatment group, n = 25) and CPA+ metformin (n = 25) treatment for 6 months."( Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome.
Liu, Y; Lv, L; Sun, Y; Tan, K, 2005
)
0.85
"To compare the effects of 3 therapeutic regimens widely used in practice--OHC alone and in combination with metformin or rosiglitazone on body weight and anthropometric proportions, hormonal and metabolic alterations."( [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
Atanasova, I; Genchev, G; Kamenov, Z; Khristov, V; Kolarov, G; Milcheva, B; Orbetsova, M; Shigarminova, R; Zakharieva, S, 2006
)
0.33
" These are of particular interest since anti-androgenic biological activity has been identified in the aquatic environment and is potentially implicated in sexual disruption alone and in combination with steroid oestrogens."( Environmental concentrations of anti-androgenic pharmaceuticals do not impact sexual disruption in fish alone or in combination with steroid oestrogens.
Brian, J; Green, C; Jobling, S; Kanda, R; Scholze, M; Williams, R, 2015
)
0.42
" monthly (n = 20; Leu+E group) in combination with TE at a dose of 1 or 2 mg daily for 1 year."( Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness.
Battista, G; Cerpolini, S; Gava, G; Martelli, V; Meriggiola, MC; Seracchioli, R, 2016
)
1.88
"Preliminary results from this retrospective observational pilot study suggest that CPA and Leu in combination with TE are equally effective in the suppression of gonadotrophins and testosterone levels over 1 year."( Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness.
Battista, G; Cerpolini, S; Gava, G; Martelli, V; Meriggiola, MC; Seracchioli, R, 2016
)
1.88
" This study aimed to compare the different effects of drospirenone (DRP)-containing COCs with cyproterone acetate (CPA)-containing COCs, combined with metformin and lifestyle modifications in women with PCOS and metabolic disorders."( Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
Feng, GM; Huang, W; Song, Y; Wang, QS; Wang, QY; Xiao, L, 2016
)
0.93
" Participants took COCs cyclically for 6 months, combined with metformin administration (1."( Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
Feng, GM; Huang, W; Song, Y; Wang, QS; Wang, QY; Xiao, L, 2016
)
0.72
"DRP-containing COCs combined with metformin and lifestyle modifications could better control BP and correct carbohydrate metabolism in women with PCOS and metabolic disorders compared with CPA-containing COCs."( Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
Feng, GM; Huang, W; Song, Y; Wang, QS; Wang, QY; Xiao, L, 2016
)
0.72
"To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance."( Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018
)
0.48
"Diane-35 in combination with orlistat or metformin is more effective in reducing androgen than Diane-35 alone."( Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018
)
0.48
"To evaluate the effects of Chinese medicine Dingkun Pill () alone or in combination with Diane-35 on patients with polycystic ovary syndrome (PCOS)."( Is There An Advantage of Using Dingkun Pill () alone or in Combination with Diane-35 for Management of Polycystic Ovary Syndrome? A Randomized Controlled Trial.
Deng, Y; Ma, RL; Ma, X; Sun, AJ; Wang, YF; Xue, W; Zhu, SY, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" Bioavailability after oral administration was nearly complete (88 +/- 20%)."( Pharmacokinetics of cyproterone acetate and its main metabolite 15 beta-hydroxy-cyproterone acetate in young healthy women.
Huber, J; Kuhnz, W; Schmidt, J; Spona, J; Täuber, U; Zeillinger, R, 1988
)
0.6
" Thus the distribution of synthetic steroids between various protein bound and nonprotein bound components in serum may influence their bioavailability at different target tissues."( Distribution and percentages of non-protein bound contraceptive steroids in human serum.
Hammond, GL; Lähteenmäki, P; Lähteenmäki, PL; Luukkainen, T, 1982
)
0.26
" Also it appears that individual differences in CPA bioavailability do not satisfactorily explain the lack of therapeutic response in about 30% of the cases."( Antiandrogens in the treatment of acne and hirsutism.
Hammerstein, J; Moltz, L; Schwartz, U, 1983
)
0.27
" The bioavailability of the active substance was complete following oral application."( [Bioavailability of cyproterone acetate after oral and intramuscular application in men (author's transl)].
Becker, H; Düsterberg, B; Klosterhalfen, H, 1980
)
0.58
" However, very little is known concerning the bioavailability and plasma levels of unmetabolized gestagens in the animal species used for chronic toxicity testing and pharmacological investigation."( Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys.
Düsterberg, B; Hümpel, M; Speck, U, 1981
)
0.49
" Factors of influence are bioavailability of the chemicals, variations in concentrations and routes of exposure, physical activity, and individual variation in rates of metabolism, distribution, and excretion."( Biomarkers as tools in human health risk assessment.
Csanády, G; Filser, JG; Greim, H; Kreuzer, P; Schwarz, L; Werner, S; Wolff, T, 1995
)
0.29
" Furthermore, IGFBP-3 proteolysis regulates the bioavailability of IGF-I."( Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty.
Flyvbjerg, A; Frystyk, J; Juul, A; Müller, J; Skakkebaek, NE, 1996
)
0.29
" The absolute bioavailability of 17beta-oestradiol after intragastric administration of 10 mg/kg was ca."( Tissue distribution of sex steroids: concentration of 17beta-oestradiol and cyproterone acetate in selected organs of female Wistar rats.
Louton, T; Schleicher, F; Schunack, W; Täuber, U, 1998
)
0.53
" Upon administration to Sprague-Dawley rats, both compounds were found to be orally bioavailable and to inhibit transactivation of liver GR."( Glucocorticoid receptor antagonism by cyproterone acetate and RU486.
Chatelain, RE; Cornell, W; Fink, C; Honer, C; Ksander, G; Marshall, P; Nam, K; Schumacher, C; Schweitzer, R; Steele, R, 2003
)
0.59
" To improve skin penetration of the poorly absorbed drug, we intended to identify the active moiety and to load it to particulate carrier systems."( Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake.
Blaschke, T; Kleuser, B; Korting, HC; Kramer, KD; Mehnert, W; Schäfer-Korting, M; Seltmann, H; Sivaramakrishnan, R; Stecová, J; Zouboulis, CC, 2007
)
1.78
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

45 patients with recently detected prostatic cancer were treated with cyproterone acetate (CPA) at a dosage of 100 mg/die. It has been postulated that a threshold dosage of CPA has mutagenic effects, but in the same way data have been published documenting that a continuous low dosage leads to a reduction of Mutagenic episodes.

ExcerptRelevanceReference
"31; mean +/- SEM) at a daily dosage of 66-150 mg/m2 (103."( Final height attainment and gonadal function in girls with precocious puberty treated with cyproterone acetate.
Balducci, R; Bozzola, M; Cisternino, M; Lorini, R; Pasquino, AM; Pucarelli, I; Segni, M; Severi, F, 1992
)
0.5
" Prolonged hormonal and incorrect treatments, mainly for too high dosage and absence of association with progesterone, assumption of oestrogens, can cause the growth of mammary tumours."( [Male transsexualism and hormonal therapy: radiologic pictures of the breast].
Bocchini, R; Cavallotti, GP; Genovese, MG; Godano, A; Grassi, G; Massara, D, 1990
)
0.28
"5 years, the mean daily dosage 115 mg."( [Ambulatory treatment of sex offenders with cyproterone acetate (Androcur). A catamnestic study].
Battegay, R; Micheroli, R, 1985
)
0.53
" Six of the patients were treated with cyproterone acetate in a dosage of 50-100 mg daily."( [Cyproterone acetate in the treatment of post-orchiectomy flushing].
Hendriksen, ON; Jansen, JE, 1989
)
1.46
"In a study of low-dose oral contraceptives, it was found that the low dosage caused insignificant effects on glucose and lipid metabolism."( Metabolic effects of three new low-dose pills: a six-month experience.
Bertolotto, A; Fioretti, P; Fruzzetti, F; Giampietro, O; Melis, G; Miccoli, R; Navalesi, R; Orlandi, MC; Ricci, C, 1989
)
0.28
" The often discussed intrinsic estrogen activity of the antiestrogens was present only in the highest dosage tested of tamoxifen."( Antiestrogen and antiandrogen administration reduce bone mass in the rat.
Bauss, F; Feldmann, S; Lempert, UG; Minne, HW; Parvizi, S; Pfeifer, M; Ziegler, R, 1989
)
0.28
" Cyproterone acetate allows differentiated treatment according to the various grades of hirsutism by modification of dosage and application."( [The concept of the causal therapy of hirsutism].
Schmidt, JB, 1986
)
1.18
" Doubling of erythromycine dosage could not prevent premenstrual exacerbation of acne."( On therapeutic approaches to some special types of acne.
Rajka, G, 1985
)
0.27
"45 patients with recently detected prostatic cancer were treated with cyproterone acetate (CPA) at a dosage of 100 mg/die."( [Therapy of prostatic cancer with cyproterone acetate].
Maier, U, 1988
)
0.79
" Side-effects are frequent, possibly as a result of the high dosage used in this study."( Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer.
de Vries, EG; Dikkeschei, LD; Mulder, NH; Sleijfer, DT; van der Ploeg, E; Willemse, PH, 1988
)
0.55
" No differences between the 3 treatment arms were observed except for medroxy-progesterone acetate, which showed less therapeutic effect in the dosage used."( Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne, FM, 1988
)
0.27
" In conclusion, this simplified method is thought to be very valuable for studies on the pharmacokinetics of CPA and 15 beta-OH-CPA, and on the relationship between the CPA dosage and the therapeutic or side effects on adrenal and gonadal steroid production."( A reversed-phase high-performance liquid chromatographic method for the simultaneous determination of serum concentrations of cyproterone acetate and 15 beta-hydroxycyproterone acetate.
Saisho, S; Shimozawa, K; Yata, J; Yodo, K, 1988
)
0.48
" One should, however, be aware that Diane contains only 2 mg cyproterone acetate (CPA) and a better effect would most probably have been obtained using a higher dosage of CPA."( A comparative study of Aldactone and Diane in the treatment of hirsutism.
Djøseland, O; Lunde, O, 1987
)
0.51
" A distinct modification of spermatogenesis and posttesticular sperm maturation processes cannot be demonstrated in the dosage range studied."( [Modification of fertility of the male by antiandrogens].
Hammerstein, J; Moltz, L; Neumann, F, 1980
)
0.26
" Thus it appears that CA has no untoward effect upon glucocorticoid secretion when given in high dosage for prolonged periods to hirsute women."( Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism.
Croxson, MS; Evans, MC; France, J; Holdaway, IM; Ibbertson, HK; Sheehan, A; Wilson, T, 1983
)
0.67
" It has become evident that DES at a dosage of 3 mg/day carries a significantly higher risk of overall cardiovascular toxicity than does cyproterone acetate, but severe cardiovascular complications did not differ between treatment groups."( Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
Schroeder, FH, 1984
)
0.47
" In four patients who showed progression of the angrogen-dependent signs (adrenarche), despite suppression of gonadotrophins, increasing the dosage of the LHRH analogue was ineffective and combined therapy with CyA was reinstituted in three of them because of accelerated growth and bone maturation."( Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate-further experience.
Ben-Zeev, Z; Kaufman, H; Kauli, R; Laron, Z; Lewin, RP; Pertzelan, A; Schally, AM; Schally, AV, 1984
)
0.5
" A high dosage "reverse sequential" therapy of 100 mg CPA on the 5th-14th days of the menstrual cycle and 40 mcg ethinyl estradiol (EE) on the 5th-25th days is used in severe cases."( [Clinical use of antiandrogens in the female].
Hammerstein, J; Moltz, L; Schwartz, U, 1980
)
0.26
"Cyproterone acetate was given to three healthy men in a dosage of 10 mg per day for 8-14 weeks."( Effects of low doses of cyproterone acetate on sperm morphology and some other parameters of reproduction in normal men.
Carlström, K; Fredricsson, B,
)
1.88
"Evaluation of occupational or environmental risk due to exposure to chemicals requires sufficient information on the toxic profiles, mechanisms of action, toxicokinetics, dose-response relation, exposure, and the target dose."( Biomarkers as tools in human health risk assessment.
Csanády, G; Filser, JG; Greim, H; Kreuzer, P; Schwarz, L; Werner, S; Wolff, T, 1995
)
0.29
" Dose-response analysis for R1881 revealed an ED50 of approximately 2 x 10(-8) M for the synthetic androgen, and comparison with other naturally occurring androgens provided the rank order of potency R1881 > androstenedione > testosterone = dihydrotestosterone."( Androgens augment vasoactive intestinal peptide- and growth hormone-releasing hormone-stimulated progestin production by rat granulosa cells.
Kasson, BG; Li, YD, 1993
)
0.29
" During our investigations of this hypothesis using a widely applied protocol, we have found that the stress induced by the process of gavage dosing can induce massive apoptosis in livers uniquely primed by withdrawal of the hepatomitogen cyproterone acetate from the hyperplastic rat liver."( Dosing-induced stress causes hepatocyte apoptosis in rats primed by the rodent nongenotoxic hepatocarcinogen cyproterone acetate.
Gill, JH; James, NH; Roberts, RA; Soames, AR; Wheeldon, EB, 1995
)
0.69
" Time course and dose-response experiments performed 48 hours after the last application of CPA showed that apoptotic nuclei with chromatin condensed at the nuclear periphery (AN) were already visible 2 hours after injection (0."( The antiandrogen cyproterone acetate induces synthesis of transforming growth factor beta 1 in the parenchymal cells of the liver accompanied by an enhanced sensitivity to undergo apoptosis and necrosis without inflammation.
Bouzahzah, B; Carr, B; Fröschl, G; Nagy, P; Oberhammer, F; Thorgeirsson, SS; Tiefenbacher, R, 1996
)
0.63
" dosing with 100 mg/kg CPA once a week for 6 successive weeks induced, as compared to controls, a significant increase in the number and area of gamma-glutamyltranspeptidase-positive foci."( Induction of micronuclei and initiation of enzyme-altered foci in the liver of female rats treated with cyproterone acetate, chlormadinone acetate, or megestrol acetate.
Allavena, A; Brambilla Campart, G; Brambilla, G; Ghia, M; Martelli, A; Mereto, E, 1996
)
0.51
"An oral dosage of CPA of 50 mg twice a day in combination with a mini-dose of DES results in rapid and reversible reduction in serum testosterone to castrate levels."( Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration.
Bruchovsky, N; Gleave, ME; Goldenberg, SL; Sullivan, LD, 1996
)
0.71
" The present study is a further investigation of the effects of CPA in mice of the C57Bl/10J strain dosed for 104 weeks."( Carcinogenicity of cyproterone acetate in the mouse.
Kalinowski, AE; Orton, TC; Tucker, MJ, 1996
)
0.62
" 75, 198-207, 1997) have suggested that dosing chemicals to newly weaned male rats for 1 month may yield a useful assay for antiandrogens."( The weanling male rat as an assay for endocrine disruption: preliminary observations.
Ashby, J; Lefevre, PA, 1997
)
0.3
" Mean A, Vc and Vss differed significantly between 2 and 14 HALO dosage (P<0."( Chronopharmacokinetic behaviour of cyproterone acetate in rabbits.
Boggio, JC; Encinas, T; Rodríguez, C; San Andrés, MD; San Andrés, MI; Vinagre, E,
)
0.41
" It is reasonable to choose a preparation with the lowest estrogen and gestagen dose and to change the dosage only after 3-4 months of use at the earliest if side effects such as bleeding irregularities occur."( [Rationale for prescribing oral contraceptives].
Teichmann, AT, 1998
)
0.3
" dosing with 100 mg kg-1 once a week for 6 successive weeks, the values of the number and area of gamma-glutamyltranspeptidase-positive foci were, as compared to controls, 15."( Induction of micronuclei and of enzyme-altered foci in the liver of female rats exposed to progesterone and three synthetic progestins.
Allavena, A; Brambilla, G; De Pascalis, CR; Ghia, M; Martelli, A; Mereto, E; Orsi, P, 1998
)
0.3
" Dose-response experiments indicated that the lowest stimulatory concentration of 17 beta-estradiol, DHT, and norgestrel is 10(-11) M, 10(-10) M, and 10(-10) M, respectively."( The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474.
Diamandis, EP; Grass, L; Luo, LY,
)
0.13
" It has been postulated that a threshold dosage of CPA has mutagenic effects, but in the same way data have been published documenting that a continuous low dosage of cyproterone acetate leads to a reduction of mutagenic episodes."( [Long-term side-effects following cyproterone acetate containing therapy in gynecology].
Regidor, M; Regidor, PA; Schindler, EM; Speer, K, 2000
)
0.78
" The present data clearly indicate that administration of CPA and TB in proper dosage combination can provide an effective, safe, and reversible method of male contraception."( Evaluation of efficacy, safety, and reversibility of combination regimen of cyproterone acetate and testosterone buciclate in bonnet monkey.
Behal, VK; Chaturvedi, PK; Pal, PC; Pruthi, JS; Rajalakshmi, M; Roy, S; Sharma, DN; Sharma, RS, 2000
)
0.54
" For the current studies, male rats were dosed for 15 days via oral gavage and euthanized on the morning of test day 15."( Evaluation of a 15-day screening assay using intact male rats for identifying antiandrogens.
Frame, SR; Ladics, GS; O'Connor, JC, 2002
)
0.31
" Results with hirsutism were satisfactory in 9 of 11 cases but the improvement was slow and often incomplete due to the weak dosage of cyproterone acetate."( [Clinical use of ethinyl estradiol in combination with cyproterone acetate. Study based on 50 cases (author's transl)].
Henrion, R; Laveissiere, MN, 1982
)
0.71
" Male Sprague-Dawley rats were dosed with the peroxisome proliferator Wy-14,643 and changes in liver gene expression examined using subtractive suppression hybridisation examined either 12 of 24hr later."( Gene expression changes in rat liver following exposure to liver growth agents: role of Kupffer cells in xenobiotic-mediated liver growth.
Crunkhorn, SE; Gibson, GG; Kramer, K; Lord, PG; Lyon, J; Plant, KE; Plant, NJ, 2004
)
0.32
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
"In this study a zero crossing technique based on continuous wavelet transform (CWT) as well as classical derivative spectrophotometry (CDS) is presented for simultaneous determination of cyproterone acetate and ethinyl estradiol in binary mixtures and commercial dosage of drug, without using prior chemical pre-treatment."( Simultaneous spectrophotometric determination of cyproterone acetate and ethinyl estradiol in tablets using continuous wavelet and derivative transform.
Abdolmaleki, P; Esmaeili, EA; Sohrabi, MR, 2010
)
0.81
" A dosage of 1 mg cyproterone acetate every second day for a period of 4 weeks induces a reduction of the relative total sebaceous gland volume of about 80% in intact mice."( The effect of a new antiandrogenic steroid, 6-chloro-17-HYDROXY-1α, 2α-methylenepregna-4,6-diene-3,20-dione acetate (cyproterone acetate) on the sebaceous glands of mice.
Elger, W; Neumann, F, 1966
)
0.79
" Testosterone-alone regimens are effective in many men but high dosing requirements and sub-optimal gonadotropin suppression in 10-30% of men limit their use."( The current state of male hormonal contraception.
Chao, JH; Page, ST, 2016
)
0.43
" Explanations for these heterogeneous findings include insufficient cross-sex hormone therapy regarding dosage or duration."( Andrology of male-to-female transsexuals: influence of cross-sex hormone therapy on testicular function.
Kliesch, S; Neuhaus, N; Schlatt, S; Schneider, F, 2017
)
0.46
" Stratification of patients by age or spironolactone dosage revealed no significant difference in testosterone levels achieved."( TESTOSTERONE LEVELS ACHIEVED BY MEDICALLY TREATED TRANSGENDER WOMEN IN A UNITED STATES ENDOCRINOLOGY CLINIC COHORT.
Chan, KJ; Jolly, D; Liang, JJ; Safer, JD, 2018
)
0.48
"The ideal dosage of cross-sex hormones remains unknown."( Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women.
Costa, EMF; Cunha, FS; Domenice, S; Mendonca, BB; Sircili, MHP, 2018
)
0.48
" The results provide a rationale for individualizing hormone therapy in transmen, by considering individual effects rather than solely relying on a standardized dosage of hormone therapy."( Variation in sensitivity and rate of change in body composition: steps toward individualizing transgender care.
Conemans, EB; den Heijer, M; Nota, NM; Simsek, S; T'Sjoen, G; van Velzen, DM, 2020
)
0.56
" The dosage of CPA taken by the exposed group (n = 165,988) was specified in three of the four included studies."( A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.
Kirollos, R; Lee, KS; Nga, VDW; Santarius, T; Yeo, TT; Zhang, JJY, 2022
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
androgen antagonistA compound which inhibits or antagonises the biosynthesis or actions of androgens.
progestinA synthetic progestogen.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
chlorinated steroidA steroid which is substituted with one or more chlorine atoms in any position.
steroid ester
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (89)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency25.11890.044717.8581100.0000AID485341
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency57.90230.100020.879379.4328AID588456
pregnane X receptorRattus norvegicus (Norway rat)Potency27.56530.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency52.17160.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency24.37200.173734.304761.8120AID1346859; AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency14.57500.004110.890331.5287AID493106
USP1 protein, partialHomo sapiens (human)Potency31.62280.031637.5844354.8130AID743255
SMAD family member 3Homo sapiens (human)Potency24.37200.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency15.16000.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency15.21080.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency20.27420.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID588515; AID588516; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency54.48270.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency68.58960.001022.650876.6163AID1224839
progesterone receptorHomo sapiens (human)Potency10.13950.000417.946075.1148AID1346784; AID1346795; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency2.18760.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency8.64850.000214.376460.0339AID588533; AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency46.07440.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency36.09630.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.93340.001530.607315,848.9004AID1224819; AID1224820; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency31.60770.375827.485161.6524AID588527; AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency61.09950.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency37.93400.000229.305416,493.5996AID588513; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080
GVesicular stomatitis virusPotency9.77170.01238.964839.8107AID1645842
67.9K proteinVaccinia virusPotency22.01630.00018.4406100.0000AID720579; AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency27.90620.001024.504861.6448AID588534; AID588535; AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency28.91500.001019.414170.9645AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency16.13010.023723.228263.5986AID588543; AID743222; AID743223; AID743241
aryl hydrocarbon receptorHomo sapiens (human)Potency3.85710.000723.06741,258.9301AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency54.42730.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency26.60320.001628.015177.1139AID1259385
activating transcription factor 6Homo sapiens (human)Potency6.16220.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency32.234119.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency10.65650.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency5.01190.10009.191631.6228AID1346983
D(1A) dopamine receptorHomo sapiens (human)Potency3.26410.02245.944922.3872AID488982
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency18.35640.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency42.20903.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency37.86770.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency56.54790.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency37.98370.000627.21521,122.0200AID651741; AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency89.12510.425612.059128.1838AID504891
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency1.41250.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency0.79430.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency22.79360.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency2.51190.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency19.95260.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency9.77170.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency9.77170.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency50.07060.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency37.57800.026622.448266.8242AID651802
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency9.77170.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency28.02210.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency28.02210.011912.222168.7989AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency2.51191.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency9.77170.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)0.22500.00000.495310.0000AID625263
Glucocorticoid receptorHomo sapiens (human)Ki0.10200.00010.38637.0010AID625263
Progesterone receptorHomo sapiens (human)IC50 (µMol)1.00000.00000.580710.0000AID162117
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.22500.00150.76005.0740AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki0.10200.00070.76537.0010AID625263
Androgen receptorHomo sapiens (human)IC50 (µMol)0.14080.00000.875310.0000AID1822374; AID38975
Androgen receptorHomo sapiens (human)Ki0.01400.00020.42407.2000AID39147
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)6.22600.00101.979414.1600AID255211; AID55258; AID625228
Androgen receptorRattus norvegicus (Norway rat)Ki0.03100.00031.21858.9270AID625228
Glycine receptor subunit betaRattus norvegicus (Norway rat)IC50 (µMol)0.22500.00150.76005.0740AID625263
Glycine receptor subunit betaRattus norvegicus (Norway rat)Ki0.10200.00070.78467.0010AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.22500.00150.80445.0740AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki0.10200.00070.78467.0010AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.22500.00150.76005.0740AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki0.10200.00070.78467.0010AID625263
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.04500.00020.552110.0000AID31540; AID31541
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.00100.00011.20929.9700AID31717; AID32025
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki0.33600.00061.353610.0000AID33574
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki0.33600.00021.494010.0000AID33574
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)2.18300.00010.813310.0000AID625163
Mu-type opioid receptorHomo sapiens (human)Ki0.88600.00000.419710.0000AID625163
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ORF73Human gammaherpesvirus 8EC50 (µMol)75.00000.06008.134632.1400AID435023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (287)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
ovulation from ovarian follicleProgesterone receptorHomo sapiens (human)
glandular epithelial cell maturationProgesterone receptorHomo sapiens (human)
regulation of DNA-templated transcriptionProgesterone receptorHomo sapiens (human)
signal transductionProgesterone receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProgesterone receptorHomo sapiens (human)
cell-cell signalingProgesterone receptorHomo sapiens (human)
positive regulation of gene expressionProgesterone receptorHomo sapiens (human)
negative regulation of gene expressionProgesterone receptorHomo sapiens (human)
paracrine signalingProgesterone receptorHomo sapiens (human)
negative regulation of phosphorylationProgesterone receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
lung alveolus developmentProgesterone receptorHomo sapiens (human)
regulation of epithelial cell proliferationProgesterone receptorHomo sapiens (human)
progesterone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
maintenance of protein location in nucleusProgesterone receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisProgesterone receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
MAPK cascadeAndrogen receptorHomo sapiens (human)
in utero embryonic developmentAndrogen receptorHomo sapiens (human)
regulation of systemic arterial blood pressureAndrogen receptorHomo sapiens (human)
epithelial cell morphogenesisAndrogen receptorHomo sapiens (human)
transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
signal transductionAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cell-cell signalingAndrogen receptorHomo sapiens (human)
spermatogenesisAndrogen receptorHomo sapiens (human)
single fertilizationAndrogen receptorHomo sapiens (human)
positive regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
positive regulation of gene expressionAndrogen receptorHomo sapiens (human)
male somatic sex determinationAndrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
intracellular receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
Leydig cell differentiationAndrogen receptorHomo sapiens (human)
multicellular organism growthAndrogen receptorHomo sapiens (human)
positive regulation of phosphorylationAndrogen receptorHomo sapiens (human)
positive regulation of MAPK cascadeAndrogen receptorHomo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of cell differentiationAndrogen receptorHomo sapiens (human)
negative regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIIAndrogen receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of developmental growthAndrogen receptorHomo sapiens (human)
animal organ formationAndrogen receptorHomo sapiens (human)
male genitalia morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell proliferationAndrogen receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationAndrogen receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAndrogen receptorHomo sapiens (human)
activation of prostate induction by androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
morphogenesis of an epithelial foldAndrogen receptorHomo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
prostate gland growthAndrogen receptorHomo sapiens (human)
prostate gland epithelium morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
mammary gland alveolus developmentAndrogen receptorHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
cellular response to steroid hormone stimulusAndrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusAndrogen receptorHomo sapiens (human)
cellular response to testosterone stimulusAndrogen receptorHomo sapiens (human)
seminiferous tubule developmentAndrogen receptorHomo sapiens (human)
non-membrane-bounded organelle assemblyAndrogen receptorHomo sapiens (human)
positive regulation of miRNA transcriptionAndrogen receptorHomo sapiens (human)
regulation of protein localization to plasma membraneAndrogen receptorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayAndrogen receptorHomo sapiens (human)
male gonad developmentAndrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (84)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
transcription coactivator bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
DNA bindingProgesterone receptorHomo sapiens (human)
nuclear steroid receptor activityProgesterone receptorHomo sapiens (human)
G protein-coupled receptor activityProgesterone receptorHomo sapiens (human)
steroid bindingProgesterone receptorHomo sapiens (human)
protein bindingProgesterone receptorHomo sapiens (human)
zinc ion bindingProgesterone receptorHomo sapiens (human)
enzyme bindingProgesterone receptorHomo sapiens (human)
identical protein bindingProgesterone receptorHomo sapiens (human)
ATPase bindingProgesterone receptorHomo sapiens (human)
estrogen response element bindingProgesterone receptorHomo sapiens (human)
nuclear receptor activityProgesterone receptorHomo sapiens (human)
transcription cis-regulatory region bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
RNA polymerase II general transcription initiation factor bindingAndrogen receptorHomo sapiens (human)
transcription coactivator bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
chromatin bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityAndrogen receptorHomo sapiens (human)
nuclear receptor activityAndrogen receptorHomo sapiens (human)
G protein-coupled receptor activityAndrogen receptorHomo sapiens (human)
signaling receptor bindingAndrogen receptorHomo sapiens (human)
steroid bindingAndrogen receptorHomo sapiens (human)
androgen bindingAndrogen receptorHomo sapiens (human)
protein bindingAndrogen receptorHomo sapiens (human)
beta-catenin bindingAndrogen receptorHomo sapiens (human)
zinc ion bindingAndrogen receptorHomo sapiens (human)
enzyme bindingAndrogen receptorHomo sapiens (human)
ATPase bindingAndrogen receptorHomo sapiens (human)
molecular adaptor activityAndrogen receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAndrogen receptorHomo sapiens (human)
POU domain bindingAndrogen receptorHomo sapiens (human)
molecular condensate scaffold activityAndrogen receptorHomo sapiens (human)
estrogen response element bindingAndrogen receptorHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (51)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneProgesterone receptorHomo sapiens (human)
nucleoplasmProgesterone receptorHomo sapiens (human)
mitochondrial outer membraneProgesterone receptorHomo sapiens (human)
cytosolProgesterone receptorHomo sapiens (human)
chromatinProgesterone receptorHomo sapiens (human)
nucleusProgesterone receptorHomo sapiens (human)
plasma membraneAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleoplasmAndrogen receptorHomo sapiens (human)
cytoplasmAndrogen receptorHomo sapiens (human)
cytosolAndrogen receptorHomo sapiens (human)
nuclear speckAndrogen receptorHomo sapiens (human)
chromatinAndrogen receptorHomo sapiens (human)
protein-containing complexAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlycine receptor subunit betaRattus norvegicus (Norway rat)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (119)

Assay IDTitleYearJournalArticle
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID38827Efficacy as a function of maximal inhibition against human androgen receptor.1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.
AID540235Phospholipidosis-negative literature compound
AID32025Binding affinity against adenosine A1 receptor from rat brain membranes using [3H]cyclohexyladenosine as radioligand.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID39322Relative binding affinity against rat ventral prostate androgen receptor using competition assay after 1 hour.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID228183Dose producing 30% decrease in blood pressure of anesthetized spontaneously hypertensive rats (SHR's)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID55258Inhibition of [3H]-R-1881 binding to rat ventral prostate cytosolic androgen receptor2000Journal of medicinal chemistry, Nov-30, Volume: 43, Issue:24
Chiral derivatives of 2-cyclohexylideneperhydro-4,7-methanoindenes, a novel class of nonsteroidal androgen receptor ligand: synthesis, X-ray analysis, and biological activity.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID228181Dose producing 10% decrease in heart rate of anesthetized spontaneously hypertensive rats (SHR's)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID32638Binding affinity against adenosine A1 receptor without GTP2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique adenosine derivative.
AID182898In vivo percent increase in rat prostate weight on subcutaneous administration of testosterone propionate along with compound at dose 1 mg/day; Expressed as percent inhibition of weight increase, mg1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Antiandrogenic activity of a series of des-A-steroid derivatives.
AID182900In vivo percent increase in rat seminal vesicles weight on subcutaneous administration of testosterone propionate along with compound at dose 1 mg/day; Expressed as percent inhibition of weight increase, mg1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Antiandrogenic activity of a series of des-A-steroid derivatives.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1822374Antagonist activity at human AR AF2 assessed as inhibition of fluorescent-labelled D11-FxxLF peptide Co-activator to receptor by TR-FRET assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Discovery of
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID753788Cytotoxicity against human LNCAP cells expressing androgen receptor after 72 hrs by MTT assay2013European journal of medicinal chemistry, Jun, Volume: 64Synthesis and preliminary in vitro biological evaluation of 7α-testosterone-chlorambucil hybrid designed for the treatment of prostate cancer.
AID1778412Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2021European journal of medicinal chemistry, Aug-05, Volume: 220Innovative C
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID39323Relative binding affinity against rat ventral prostate androgen receptor using competition assay after 18 hours.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID39304In vitro binding affinity towards androgen receptor of castrated rat prostate using [3H]testosterone as radioligand 24 hr after administration1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Antiandrogenic activity of a series of des-A-steroid derivatives.
AID38975Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID39147Binding affinity for human androgen receptor in transiently-transfected COS-1 cells.1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.
AID31540Displacement of [3H]DPCPX from adenosine A1 receptor of rat cortical membranes without GTP2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique adenosine derivative.
AID232320Ratio of A1-receptor binding to that of A2-receptor binding1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.
AID1778411Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2021European journal of medicinal chemistry, Aug-05, Volume: 220Innovative C
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID33592Binding to Adenosine A2 receptor was measured in ADA-pretreated rat striatal membranes using [3H]-CGS- 216801990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.
AID684109Cytotoxicity against androgen independent human PC3 cells assessed as cell viability at 50 uM after 24 hrs by alamar blue assay2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
"True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.
AID547622Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID269844Binding affinity at AR relative to flutamide2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID473870Cytotoxicity against human androgen receptor positive LNCAP cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
First synthesis of separable isomeric testosterone dimers showing differential activities on prostate cancer cells.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID176392Antiandrogenic activity as the dose required to inhibit testosterone propionate-induced rat ventral prostate weight gain in castrated immature rat by 50%.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID547804Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID753787Cytotoxicity against androgen receptor deficient human PC3 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, Jun, Volume: 64Synthesis and preliminary in vitro biological evaluation of 7α-testosterone-chlorambucil hybrid designed for the treatment of prostate cancer.
AID161974Efficacy as a function of maximal inhibition against human progesterone receptor B (hPR-B).1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID31541Displacement of [3H]DPCPX from adenosine A1 receptor of rat cortical membranes with GTP2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique adenosine derivative.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID1778410Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2021European journal of medicinal chemistry, Aug-05, Volume: 220Innovative C
AID33574Binding affinity against adenosine A2 receptor from rat striatum using [3H]NECA as radioligand.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID162117Antagonistic activity against human progesterone receptor B (hPR-B) in co-transfected CV-1 cells.1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.
AID547621Cytotoxicity against BESM cells after 88 hrs by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID39302In vitro binding affinity towards androgen receptor of castrated rat prostate using [3H]testosterone as radioligand 30 min after administration1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Antiandrogenic activity of a series of des-A-steroid derivatives.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID234758Selectivity determined as Ratio of Ki(nM) of A1 adenosine receptor to the Ki(nM) of A2 adenosine receptor1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID473871Cytotoxicity against human androgen receptor negative PC3 cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
First synthesis of separable isomeric testosterone dimers showing differential activities on prostate cancer cells.
AID31717Adenosine A1 receptor binding was measured in adenosine deaminase (ADA) pretreated rat cortical membranes using [3H]cyclohexyladenosine in the presence of 2-chloroadenosine1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1346888Human Androgen receptor (3C. 3-Ketosteroid receptors)1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,735)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990536 (30.89)18.7374
1990's510 (29.39)18.2507
2000's389 (22.42)29.6817
2010's233 (13.43)24.3611
2020's67 (3.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 81.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index81.75 (24.57)
Research Supply Index7.69 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index149.54 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (81.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials339 (18.37%)5.53%
Reviews159 (8.62%)6.00%
Case Studies171 (9.27%)4.05%
Observational9 (0.49%)0.25%
Other1,167 (63.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (34)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Bioequivalence Study of 2 mg Cyproterone Acetate and 0.035 mg Ethinyl Estradiol in Indonesian Healthy Females [NCT04964193]24 participants (Actual)Interventional2019-03-12Completed
A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of Polycystic Ovary Syndrome [NCT03264638]Phase 2315 participants (Anticipated)Interventional2016-10-01Recruiting
Study to Evaluate Physician Awareness and Knowledge of Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Monotherapies in Europe: an Observational Post-Authorisation Joint Safety Study (Safe-CAM) [NCT04925180]600 participants (Actual)Observational2021-10-18Completed
Comparison of Efficacy and Safety of Tricilest (Norgestimate-ethinyl Estradiol) and Diane-35 (Cyproterone Acetate-ethinyl Estradiol) in the Treatment of Acne Vulgaris [NCT00752635]Phase 448 participants (Actual)Interventional2004-09-30Completed
Phase IV Study of the Use of Two Preparations of Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation of Hyper-androgenic Origin [NCT01103518]Phase 4100 participants (Anticipated)Interventional2009-12-31Active, not recruiting
The Influence of Sex Steroid Hormones on Serotonin Transporter Binding in the Human Brain Investigated by Positron Emission Tomography [NCT01065220]Phase 432 participants (Actual)Interventional2010-02-28Completed
Efficacy and Tolerance of Cyproterone Acetate Versus Medroxyprogesterone Acetate Versus Venlafaxine LP in the Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Patients Treated for a Prostate Adenocarcinoma [NCT01011751]Phase 3311 participants (Actual)Interventional2004-04-30Completed
OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women [NCT02744131]100 participants (Anticipated)Interventional2016-05-31Recruiting
Prospective Observational Non-interventional Study of Correlation of Treatment With Androcur, Disease Stage, Testosterone Level, Age With Sexual Function and Erectile Dysfunction (Measured by IIEF-5 Validated Questionnaire) [NCT00919022]194 participants (Actual)Observational2009-08-31Terminated
A Prospective Controlled Randomized Multicenter Trial to Evaluate the Effect of a Structurized Multifactorial Behavior Modifying Consultation and Support Programme DiaNe for People With Diabetic Nephropathy [NCT00782847]Phase 3125 participants (Actual)Interventional2004-07-31Completed
"Effect of Cyproterone Acetate / Ethinyl Estradiol Combination on Periodontal Tissue and High Sensitivity C- Reactive Protein Levels in Women With Polycystic Ovary Syndrome Having Gingivitis." [NCT05657171]50 participants (Anticipated)Observational2022-12-12Not yet recruiting
Phase III Randomized Comparison of Pelvic Radiotherapy Alone vs Pelvic Radiotherapy Plus the LHRH Analogue Goserelin and Cyproterone Acetate in Carcinoma of the Prostate at High Risk for Metastasis [NCT00849082]Phase 30 participants Interventional1987-05-31Completed
Measure of Androcur Effects on Quality of Life at Prostate Cancer Patients [NCT00908674]245 participants (Actual)Observational2008-06-30Completed
Effects of Sex Steroid Hormones on Serotonin Synthesis and Degradation Measured With PET [NCT02715232]Phase 492 participants (Anticipated)Interventional2017-02-06Recruiting
Randomized Trial Comparing Functional Digestive Outcomes Related to Two Types of Management of Rectal Endometriosis: Continuous Hormonal Treatment and Curative Surgery [NCT01973816]Phase 378 participants (Anticipated)Interventional2014-11-30Recruiting
The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants [NCT02027337]Phase 4200 participants (Anticipated)Interventional2013-12-31Recruiting
Institute of HIV Research and Innovation (IHRI) [NCT04590417]20 participants (Actual)Interventional2020-10-01Active, not recruiting
The Effects of Treatment With Oral Contraceptive Pill Containing Ethinyl Estradiol-Cyproterone Acetate and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in Polycystic Ovarian Syndrome [NCT02866786]Phase 4101 participants (Actual)Interventional2016-08-15Completed
Effects of Treatment With Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Serum Inflammatory Markers in Patients With Polycystic Ovary Syndrome (PCOS) [NCT02689843]Early Phase 190 participants (Actual)Interventional2018-02-01Completed
Comparative Controlled Clinical Trial of Two Pharmacological Treatments of Pedophilia [NCT00601276]Phase 348 participants (Anticipated)Interventional2007-12-31Terminated
The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives [NCT00428311]Phase 450 participants Interventional2004-04-30Completed
The Effect of Short Term Use of Finasteride Versus Cyproterone Acetate on Perioperative Blood Loss With Mono Polar Transurethral Resection of Prostate [NCT04848181]Early Phase 160 participants (Actual)Interventional2019-07-01Completed
A Dose-ranging Clinical Trial to Study the Efficacy and Safety of DR-2031 for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients [NCT00196339]Phase 2315 participants (Actual)Interventional2005-06-30Completed
The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization [NCT01752270]Phase 4100 participants (Anticipated)Interventional2012-12-31Not yet recruiting
Drug Utilization Study on Diane®-35 (and Generics) in European Healthcare Databases [NCT02349399]26,065 participants (Actual)Observational2015-05-01Completed
Effect of Decreasing Iron Tissue Depots on the Cardiovascular Risk of Women With Polycystic Ovary Syndrome [NCT02460445]37 participants (Actual)Interventional2015-01-31Completed
Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial [NCT01573377]40 participants (Actual)Interventional2012-02-29Completed
Study to Evaluate Physician Knowledge of Safety and Safe Use Information for Diane-35 and Its Generics in Europe: An Observational Post-Authorisation Safety Study [NCT02410031]759 participants (Actual)Observational2015-06-26Completed
A Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of CyPat (Cyproterone Acetate [CA]) for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patien [NCT00005623]Phase 30 participants Interventional1999-12-31Completed
Evaluation of Periodontal Status and High Sensitivity C Reactive Protein Levels in Female Patients Diagnosed With Polycystic Ovary Syndrome on Cyproterone Acetate/Ethinyl Estradiol Combination Regimen: a Cross Sectional Study [NCT05021861]150 participants (Anticipated)Observational2021-11-30Not yet recruiting
Intermittent Hormone Therapy for Newly Diagnosed Metastatic Prostate Cancer [NCT00363285]Phase 3900 participants (Anticipated)Interventional2003-01-31Recruiting
Functional Study of the Hypothalamus in High-resolution Magnetic Resonance Imaging (MRI) in Women With Polycystic Ovary Syndrome (PCOS): a Comparative Study [NCT03043924]52 participants (Anticipated)Interventional2017-09-26Active, not recruiting
A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients With Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer [NCT00003653]Phase 31,386 participants (Actual)Interventional1999-01-05Completed
The Efficacy and Safety Study of Tung's Acupuncture for Improving Ovarian Function of Polycystic Ovarian Syndrome: a Randomised Controlled Trial [NCT02729545]Phase 260 participants (Actual)Interventional2016-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02729545 (9) [back to overview]Change in LH/FSH Ratio From Baseline to the 24th Week
NCT02729545 (9) [back to overview]Change in LH/FSH Ratio From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in Body Mass Index (BMI) From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in FSH From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in LH From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in Ovarian Volume From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in Polycystic Ovary Number From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in the Number of Bleeding Events From Baseline to the End of Treatment
NCT02729545 (9) [back to overview]Changes in Total Testosterone (TT) From Baseline to the End of Treatment
NCT04964193 (2) [back to overview]Pharmacokinetics Parameter
NCT04964193 (2) [back to overview]Pharmacokinetics Parameter

Change in LH/FSH Ratio From Baseline to the 24th Week

the change in LH/FSH ratio, values at the 24th week minus the values at baseline (NCT02729545)
Timeframe: baseline to the 24th week

Interventionratio (Mean)
Tung's Acupuncture-0.39
CPA/EE-0.44

[back to top]

Change in LH/FSH Ratio From Baseline to the End of Treatment

the change in LH/FSH ratio, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionratio (Mean)
Tung's Acupuncture-0.66
CPA/EE-0.96

[back to top]

Changes in Body Mass Index (BMI) From Baseline to the End of Treatment

the changes in BMI, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionkg/m^2 (Mean)
Tung's Acupuncture-0.90
CPA/EE-0.44

[back to top]

Changes in FSH From Baseline to the End of Treatment

changes in follicle-stimulating hormone (FSH), values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

InterventionmIU/mL (Mean)
Tung's Acupuncture-0.49
CPA/EE-0.22

[back to top]

Changes in LH From Baseline to the End of Treatment

changes in luteinizing hormone(LH), values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

InterventionmIU/mL (Mean)
Tung's Acupuncture-3.92
CPA/EE-5.66

[back to top]

Changes in Ovarian Volume From Baseline to the End of Treatment

changes in ovarian volume, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventioncm^3 (Mean)
Tung's Acupuncture-1.70
CPA/EE-1.03

[back to top]

Changes in Polycystic Ovary Number From Baseline to the End of Treatment

the changes in polycystic ovary number, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionpolycystic ovaries (Mean)
Tung's Acupuncture0.00
CPA/EE0.00

[back to top]

Changes in the Number of Bleeding Events From Baseline to the End of Treatment

Changes in the number of bleeding events, values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionbleeding events (Mean)
Tung's Acupuncture0.66
CPA/EE1.21

[back to top]

Changes in Total Testosterone (TT) From Baseline to the End of Treatment

changes in total testosterone (TT) , values after 12-week treatment minus the values at baseline (NCT02729545)
Timeframe: baseline and 12 weeks

Interventionnmol/L (Mean)
Tung's Acupuncture-0.67
CPA/EE-0.33

[back to top]

Pharmacokinetics Parameter

Area Under Curve from 0 to 72 hours (AUCt) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing

,
Interventionpg*hr/mL (Mean)
AUC0-t of Cyproterone AcetateAUC0-t of Ethinyl Estradiol
Diane-35 Sugar-coated Tablet127.54842.56
Elzsa Film-coated Tablet132.56870.45

[back to top]

Pharmacokinetics Parameter

Maximum plasma concentration (Cmax) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing

,
Interventionpg/mL (Mean)
Cmax of Cyproterone AcetateCmax of Ethinyl Estradiol
Diane-35 Sugar-coated Tablet16.2093.61
Elzsa Film-coated Tablet17.39103.69

[back to top]